Fairway Medical Technologies Inc.
Fairway Medical Technologies Inc. of
Houston has received $3.8 million in federal funding to conduct Phase II research
on optoacoustic breast and prostate cancer diagnostic methods. The NIH’s National
Cancer Institute has awarded the company $2.7 million to develop its laser-ultrasound-nanotechnology
system for animal tests and a $1.1 million Small Business Innovation Research grant
for the development of a commercial prostate cancer early-detection system. The
laser-based technology is used with gold nanorods bound to antibodies to allow higher
contrast and definition. It has the potential to detect tumors as small as 2 mm
and can differentiate between benign and malignant tumors.
Seno Medical Instruments of San Antonio
has purchased Fairway Medical’s optoacoustic technology and will introduce
it as a real-time breast cancer detection and diagnosis method. The company will
help fund the system’s initial commercialization steps.
MORE FROM PHOTONICS MEDIA